Health Canada Clears Palisade Bio To Commence Phase 1 Clinical Study for Lead Program, PALI-2108 For Treatment Of Ulcerative Colitis
Portfolio Pulse from Benzinga Newsdesk
Palisade Bio has received approval from Health Canada to begin a Phase 1 clinical study for its lead program, PALI-2108, aimed at treating ulcerative colitis. The study will explore single and multiple ascending doses and food effects. The global ulcerative colitis market is projected to reach $10 billion by 2028.
October 10, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Palisade Bio has received a No Objection Letter from Health Canada to start a Phase 1 clinical trial for PALI-2108, targeting ulcerative colitis. This regulatory approval is a positive step for the company as it enters a growing market.
The approval from Health Canada allows Palisade Bio to advance its clinical trials, which is a critical step in drug development. The growing ulcerative colitis market adds potential value to successful trial outcomes, likely boosting investor confidence and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100